Source: American Society for Radiation Oncology From: sciencedaily.com The first report from a phase II, multi-center clinical trial indicates that a newer, more aggressive form of radiation therapy — stereotactic radiation — can extend long-term survival for some patients with stage-IV cancers while maintaining their quality of life. The study is published in the January issue of International Journal of …
Clinical Trial Saves Life of Stage 4 Kidney Cancer Patient
By: Bianca Castro From: nbcdfw.com When a well-known journalist in Dallas learned he had stage 4 kidney cancer, he was told he had three, possibly four, years to live. One year, later, the tumor threatening his life is gone and it’s thanks to a clinical trial at UT Southwestern. Robert Wilonsky will tell you there’s nothing special about him. He’ll …
Mayo researchers ID potential new treatment for one type of triple-negative breast cancer
Source: Mayo Clinic From: eurekalert.org Mayo Clinic researchers have identified the drug estradiol as a potential new treatment for a subset of women with triple-negative breast cancer. Their findings are published in the Proceedings of the National Academy of Sciences of the United States of America. “Triple-negative breast cancer is a form of breast cancer that lacks expression of estrogen …
Puma Biotechnology Announces Top Line Results of the Phase III NALA Trial of Neratinib in Patients with HER2-Positive Metastatic Breast Cancer
SOURCE: Puma Biotechnology, Inc. From: apnews.com Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced top line results from the Phase III NALA trial of the Company’s lead drug candidate PB272 (neratinib) in patients with HER2-positive metastatic breast cancer who have failed two or more prior lines of HER2-directed treatments (third-line disease) in the setting of metastatic disease. The Phase …
Puma Biotechnology Presents Results of Patient Reported Outcomes in Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
From: businesswire.com Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, is presenting updated results from a Phase II clinical trial of Puma’s drug neratinib at the 2018 San Antonio Breast Cancer Symposium (SABCS) that is currently taking place in San Antonio, Texas. The presentation entitled, “The impact of neratinib with or without anti-diarrheal prophylaxis on health-related quality of life in …
ONC201 Trial Begins for Endometrial and Breast Cancer
Oncoceutics, Inc. announced today that the first patient has been treated in a clinical trial of ONC201 for patients with certain types of advanced endometrial and breast cancer. The Phase II trial is led by Alexandra Zimmer, MD, Assistant Research Physician at the Women’s Malignancies Branch at the National Cancer Institute (NCI) Center for Cancer Research, part of the National …